Drugs.com - New Drug Approvals

Celltrion Announces U.S. FDA Approval of Additional Presentation of Steqeyma (ustekinumab-stba), Expanding Dosing Options for Pediatric Patients

INCHEON, South Korea, June 15, 2025 -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of Steqeyma® (ustekinumab-stba), a biosimilar to Stelara® (ustekinumab), in a 45mg/0.5mL...

Jun 21, 2025 - 03:00
 0
Celltrion Announces U.S. FDA Approval of Additional Presentation of Steqeyma (ustekinumab-stba), Expanding Dosing Options for Pediatric Patients
INCHEON, South Korea, June 15, 2025 -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of Steqeyma® (ustekinumab-stba), a biosimilar to Stelara® (ustekinumab), in a 45mg/0.5mL...
Read More

Tags:

Previous Article

Lilly to Offer All Approved Doses of Zepbound (tirzepatide) Single-Dose Vials Th...

Next Article

BYD Set to Dominate NEV Market in Southeast Asia, Starting with Thailand

Related Posts

U.S. FDA Approves Expanded Indication for AbbVie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus

U.S. FDA Approves Expanded Indication for AbbVie's Mavy...

Jun 12, 2025  0

FDA Approves mNEXSPIKE (COVID-19 Vaccine, mRNA) to Prevent COVID-19

FDA Approves mNEXSPIKE (COVID-19 Vaccine, mRNA) to Prev...

Jun 3, 2025  0

Mirum’s Livmarli Now FDA Approved in Tablet Formulation

May 12, 2025  0